Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07THJ
|
|||
| Former ID |
DIB013584
|
|||
| Drug Name |
IPH-3102
|
|||
| Synonyms |
IPH-31XX; TLR-3 receptor agonist (cancer), Innate Pharma; Toll-like receptor 3 agonist (cancer),Innate Pharma
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Company |
Innate Pharma SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 3 (TLR3) | Target Info | Agonist | [2] |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Toll receptor signaling pathway | |||
| Pathway Interaction Database | Endogenous TLR signaling | |||
| Reactome | Ligand-dependent caspase activation | |||
| MyD88-independent TLR3/TLR4 cascade | ||||
| Trafficking and processing of endosomal TLR | ||||
| RIP-mediated NFkB activation via ZBP1 | ||||
| TRIF-mediated programmed cell death | ||||
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | ||||
| IKK complex recruitment mediated by RIP1 | ||||
| TRAF6 mediated induction of TAK1 complex | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Cytosolic sensors of pathogen-associated DNA | ||||
| Toll-Like Receptors Cascades | ||||
| MyD88-independent cascade | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037691) | |||
| REF 2 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.